Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-039436
Filing Date
2025-04-25
Accepted
2025-04-25 16:15:16
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5681
  Complete submission text file 0001104659-25-039436.txt   7673
Mailing Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104
Business Address 3675 MARKET STREET SUITE 401 PHILADELPHIA PA 19104 2674916422
Carisma Therapeutics Inc. (Subject) CIK: 0001485003 (see all company filings)

EIN.: 262025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-87951 | Film No.: 25874223
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address THISTLE HOUSE, 4 BURNABY STREET HAMILTON Bermuda HM11
Business Address THISTLE HOUSE, 4 BURNABY STREET HAMILTON Bermuda HM11 847-932-7900
AbbVie Biotechnology Ltd (Filed by) CIK: 0002014668 (see all company filings)

EIN.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A